Kiniksa Pharmaceuticals International, plc KNSA
94.13 USD -0.89 (-0.94%)
Nov 11, 2026, 10:41 AM EST
93.93 Day range 96.05
37.02 52-week range 99.31
- YTD
- +128.19%
- 1 year
- +132.02%
News
defenseworld.net AlphaCentric Advisors LLC Acquires New Position in Kiniksa Pharmaceuticals International, plc $KNSA AlphaCentric Advisors LLC bought a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) during the undefined quarter, according to its most recent 13F filing with the…
zacks.com Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
benzinga.com JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122 JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.
benzinga.com Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101 Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $90 to $101.
benzinga.com Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102 Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $99 to $102.- benzinga.com Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110 Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com Crude Oil Moves Lower; Corning Earnings Top Views U.S. stocks mostly rose Tuesday: S&P 500 +0.5%, Nasdaq +1.1%, while Dow slipped. Oil fell 1.5%; Corning beat Q3 estimates.
benzinga.com Pentair, JetBlue Airways, Hawkins And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow slips 0.1%; Pentair jumps 9.8% on strong Q3 results and raised FY26 sales guidance, with several stocks rallying.
benzinga.com Kiniksa Pharmaceuticals Q3 2026 Earnings Call Transcript Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
benzinga.com Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $980.000M-$995.000M to $1.045B-$1.050B vs $996.102M Est Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $980.000 million-$995.000 million to $1.045 billion-$1.050 billion vs $996.102 million estimate.- benzinga.com Kiniksa Pharmaceuticals Q3 EPS $0.56 Beats $0.37 Estimate, Sales $285.970M Beat $260.611M Estimate Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.37 by 51.35 percent. This is a 143.48 percent increase over…
benzinga.com Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90 Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.- benzinga.com JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107 JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $72 to $107.
- benzinga.com Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98 Canaccord Genuity analyst Edward Nash maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $64 to $98.
- benzinga.com Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99 Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $72 to $99.
benzinga.com Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100 Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $100.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular session. The company's market cap stands at $936.3 million. As per the press release, Q2 earnings came out…
benzinga.com Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results US stocks trade higher, Dow up 1% on Tuesday. Boeing gains 5% after reporting Q2 results. Kiniksa Pharma, OPKO Health, Itron, up over 20%.
benzinga.com Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting better-than-expected earnings and raising FY26 guidance.
benzinga.com Kiniksa Pharmaceuticals Q2 EPS $0.30 Beats $0.27 Estimate, Sales $243.600M Beat $225.457M Estimate Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.27 by 11.11 percent. This is a 30.43 percent increase over…
benzinga.com Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $930.000 million-$945.000 million to $980.000 million-$995.000 million vs $940.106 million estimate.- benzinga.com Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75 Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $75.
- benzinga.com Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $74 Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $57 to $74.
benzinga.com Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $72 Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $59 to $72.- benzinga.com Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $60 Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $50 to $60.
- benzinga.com Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $59 Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $58 to $59.
- benzinga.com Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $57 Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $53 to $57.
- benzinga.com Jefferies Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $71 Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $58 to $71.
benzinga.com CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.- benzinga.com Kiniksa Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $900.000M-$920.000M to $930.000M-$945.000M vs $913.245M Est Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $900.000 million-$920.000 million to $930.000 million-$945.000 million vs $913.245 million estimate.
- benzinga.com Kiniksa Pharmaceuticals Q1 EPS $0.27 Beats $0.19 Estimate, Sales $214.300M Beat $206.091M Estimate Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.19 by 42.11 percent. This is a 145.45 percent increase over…
benzinga.com Earnings Scheduled For April 28, 2026 
benzinga.com Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month Oversold stocks in health care sector present buying opportunity. RSI compares stock's strength on up/down days & predicts short-term performance. Top oversold stocks: KNSA (28) NNOX (28.2) RNA…- benzinga.com Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $58 Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $53 to $58.
benzinga.com The Analyst Verdict: Kiniksa Pharmaceuticals In The Eyes Of 4 Experts - benzinga.com Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $53 Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $50 to $53.
- benzinga.com Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $53 Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $50 to $53.
- benzinga.com Kiniksa Pharmaceuticals Q4 Earnings Assessment
- benzinga.com Kiniksa Pharmaceuticals Sees FY2026 Sales $900.000M-$920.000M vs $902.168M Est Kiniksa Pharmaceuticals (NASDAQ:KNSA) sees FY2026 sales of $900.000 million-$920.000 million vs $902.168 million analyst estimate.
- benzinga.com Kiniksa Pharmaceuticals Q4 EPS $0.17 Misses $0.38 Estimate, Sales $202.127M Beat $195.005M Estimate. Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.38 by 54.67 percent. This is a 241.67 percent increase over…
- benzinga.com Earnings Scheduled For February 24, 2026
benzinga.com Earnings Scheduled For October 28, 2025 
benzinga.com Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - benzinga.com Earnings Scheduled For July 29, 2025
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 10 Health Care Stocks Whale Activity In Today's Session